Cargando…
Can (99)Tc(m)-3PRGD(2)(α(ν)β(3)) and (18)F-FDG dual-tracer molecular imaging change the therapeutic strategy for progressive refractory differentiated thyroid cancer: Case report
The management of radioiodine refractory differentiated thyroid cancer (RAIR-DTC) represents a major challenge in thyroid cancer. The American Thyroid Association guidelines recommend the use of tyrosine kinase inhibitors (TKIs) for RAIR-DTC that does not respond to conventional treatment. Currently...
Autores principales: | Zhang, Yu, Li, Yuxuan, Lin, Zhiyi, Chen, Wenxin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901998/ https://www.ncbi.nlm.nih.gov/pubmed/36749225 http://dx.doi.org/10.1097/MD.0000000000032751 |
Ejemplares similares
-
Clinical impact of dual-tracer FDOPA and FDG PET/CT for the evaluation of patients with parkinsonian syndromes
por: Emsen, Berivan, et al.
Publicado: (2020) -
(99)Tc(m)-MDP Imaging of Osteopetrosis: Case Report
por: Zheng, Li-Chun, et al.
Publicado: (2015) -
1-hour versus 3-hour (99m)Tc-PYP imaging to evaluate suspected cardiac transthyretin amyloidosis
por: Nichols, Kenneth J., et al.
Publicado: (2023) -
Clinical role of (18)F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer
por: Tang, Xiaowei, et al.
Publicado: (2023) -
Is dual-phase SPECT/CT with (99m)Tc-sestamibi better than single-phase SPECT/CT for lesion localization in patients with hyperparathyroidism?
por: Lee, Suk Hyun, et al.
Publicado: (2020)